文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

利拉鲁肽治疗南非HIV感染者肥胖的疗效与可接受性

Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa.
PubMed 文献 · Clin Infect Dis · 2026-05-28

LIROH试验在南非农村纳入40例BMI≥30 kg/m2的HIV感染者,开放标签给予利拉鲁肽3.0 mg每日一次共12周。受试者体重、腰围和HbA1c显著下降,抑郁症状、睡眠质量及心理生活质量改善,停药后体重和腰围明显反弹。

要点

  • 利拉鲁肽3.0 mg每日一次12周可降低HIV感染者体重、腰围和HbA1c。
  • 治疗期间抑郁症状、睡眠质量和心理生活质量显著改善。
  • 停药后体重和腰围显著反弹,代谢外指标变化不明显。

核心结论

  • 利拉鲁肽联合生活方式咨询在南非农村HIV感染者中可改善代谢健康,且干预可接受。
  • 停药后体重和腰围显著反弹,而抑郁、睡眠和生活质量变化轻微。

研究设计与样本

  • IV期开放标签临床试验(LIROH),2024年5月至9月在夸祖鲁-纳塔尔招募40例BMI≥30 kg/m2的HIV感染者。
  • 干预为利拉鲁肽3.0 mg每日一次共12周,评估12周和24周可接受性。

主要发现

  • 体重变化-2.9%(-1.0至-4.5%),腰围-5.6 cm(-8.2至-2.9),HbA1c -0.3%(-0.4至-0.2)。
  • 治疗期间抑郁症状、睡眠质量和心理生活质量均显著改善。

临床怎么用

  • 对BMI≥30 kg/m2的HIV感染者,可考虑利拉鲁肽3.0 mg每日一次联合生活方式咨询改善体重和代谢指标。
  • 需告知停药后体重和腰围可能反弹,代谢外获益在停药后变化不明显。

局限性

  • 开放标签设计、样本量小(40例)、单中心、随访至24周,长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Liraglutide for Obesity in HIV (LIROH) trial, we evaluated the efficacy and acceptability of liraglutide plus lifestyle counselling on weight and cardiometabolic health markers, along with the effect of discontinuation of therapy, among people with HIV (PWH) and a body mass index (BMI) ≥ 30 kg/m2 in rural South Africa. METHODS: From May - September 2024, we enrolled 40 PWH in KwaZulu-Natal in a Phase IV, open-label clinical trial of liraglutide 3.0 mg daily for 12 weeks. Key cardiometabolic health outcomes included changes in weight, waist circumference, and hemoglobin A1c (HbA1c). We also assessed depression, quality of life (QoL) and sleep quality. We also assessed acceptability of the intervention based on enrollment fraction and retention at 12 weeks and 24 weeks. RESULTS: We screened 52 participants, of whom 44 (85%) were eligible and 40 (91%) consented to enroll. Thirty-eight (95%) completed the study, with 2 (5%) discontinuing treatment due to relocation. Participants experienced substantial reductions in weight and waist circumference, and mean HbA1c (Weight: -2.9% [(-1.0-4.5%]; waist: -5.6 cm [-8.2 to -2.9]; HbA1c: -0.3% [-0.4 to -0.2]). Moreover, depressive symptoms, sleep quality, and psychological QoL all improved significantly with treatment. Weight and waist circumference rebounded significantly off treatment. The changes in depression, sleep quality and QoL were negligible post-treatment. CONCLUSIONS: This trial is among the first studies of GLP-1 RAs in Southern Africa and demonstrates that this class for obesity treatment among PWH in this region has efficacy to improve metabolic health and that the study intervention was acceptable in this population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Behuhuma N, Gasa G, Derache A, et al. Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa. Clin Infect Dis. 2026. PMID: 42203210. doi:10.1093/cid/ciag337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。